NGL Fine-Chem Limited (NGLFINE) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.056x

Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs167.72 Million ≈ $1.81 Million USD) by net assets (Rs3.00 Billion ≈ $32.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NGLFINE equity financing ratio to measure how much of total assets are equity-financed.

NGL Fine-Chem Limited - Cash Flow Conversion Efficiency Trend (2009–2026)

This chart illustrates how NGL Fine-Chem Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NGL Fine-Chem Limited (NGLFINE) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

NGL Fine-Chem Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NGL Fine-Chem Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Hexindo Adiperkasa Tbk
JK:HEXA
0.038x
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
-0.005x
Evans Bancorp Inc
NYSE MKT:EVBN
-0.022x
Paiho Shih Holdings Corp
TW:8404
0.039x
Shin Yang Shipping Corporation Bhd
KLSE:5173
0.046x
AURORA EIENDOM NK 75
F:IL7
N/A
Journey Energy Inc
TO:JOY
0.041x
GSI Technology Inc
NASDAQ:GSIT
-0.096x

Annual Cash Flow Conversion Efficiency for NGL Fine-Chem Limited (2009–2026)

The table below shows the annual cash flow conversion efficiency of NGL Fine-Chem Limited from 2009 to 2026. For the full company profile with market capitalisation and key ratios, see NGL Fine-Chem Limited market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-03-31 Rs3.29 Billion
≈ $35.60 Million
Rs395.40 Million
≈ $4.28 Million
0.120x -5.31%
2025-03-31 Rs2.82 Billion
≈ $30.54 Million
Rs358.22 Million
≈ $3.87 Million
0.127x +62.77%
2024-03-31 Rs2.63 Billion
≈ $28.40 Million
Rs204.65 Million
≈ $2.21 Million
0.078x -50.85%
2023-03-31 Rs2.23 Billion
≈ $24.07 Million
Rs352.86 Million
≈ $3.82 Million
0.159x +133.07%
2022-03-31 Rs2.03 Billion
≈ $21.98 Million
Rs138.25 Million
≈ $1.50 Million
0.068x -61.59%
2021-03-31 Rs1.54 Billion
≈ $16.70 Million
Rs273.54 Million
≈ $2.96 Million
0.177x -14.36%
2020-03-31 Rs989.61 Million
≈ $10.70 Million
Rs204.64 Million
≈ $2.21 Million
0.207x +115.34%
2019-03-31 Rs921.23 Million
≈ $9.96 Million
Rs88.47 Million
≈ $956.76K
0.096x -69.07%
2018-03-31 Rs720.42 Million
≈ $7.79 Million
Rs223.65 Million
≈ $2.42 Million
0.310x +84.86%
2017-03-31 Rs585.12 Million
≈ $6.33 Million
Rs98.26 Million
≈ $1.06 Million
0.168x -11.71%
2016-03-31 Rs442.15 Million
≈ $4.78 Million
Rs84.10 Million
≈ $909.54K
0.190x -16.82%
2015-03-31 Rs328.16 Million
≈ $3.55 Million
Rs75.04 Million
≈ $811.54K
0.229x +1990.49%
2014-03-31 Rs245.44 Million
≈ $2.65 Million
Rs-2.97 Million
≈ $-32.11K
-0.012x -932.61%
2013-03-31 Rs200.15 Million
≈ $2.16 Million
Rs-234.46K
≈ $-2.54K
-0.001x -101.43%
2012-03-31 Rs171.06 Million
≈ $1.85 Million
Rs14.01 Million
≈ $151.47K
0.082x -66.15%
2011-03-31 Rs160.59 Million
≈ $1.74 Million
Rs38.85 Million
≈ $420.12K
0.242x +140.92%
2010-03-31 Rs136.48 Million
≈ $1.48 Million
Rs13.70 Million
≈ $148.20K
0.100x +413.97%
2009-03-31 Rs109.35 Million
≈ $1.18 Million
Rs-3.50 Million
≈ $-37.82K
-0.032x --

About NGL Fine-Chem Limited

NSE:NGLFINE India Drug Manufacturers - General
Market Cap
$220.00 Million
Rs20.34 Billion INR
Market Cap Rank
#16166 Global
#842 in India
Share Price
Rs3292.80
Change (1 day)
+1.00%
52-Week Range
Rs1204.60 - Rs3292.80
All Time High
Rs3292.80
About

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more